Bone Biologics Corp
NASDAQ:BBLG
Bone Biologics Corp
Net Income (Common)
Bone Biologics Corp
Net Income (Common) Peer Comparison
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Bone Biologics Corp
NASDAQ:BBLG
|
Net Income (Common)
-$8.9m
|
CAGR 3-Years
-70%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Net Income (Common)
$6B
|
CAGR 3-Years
5%
|
CAGR 5-Years
2%
|
CAGR 10-Years
4%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Income (Common)
$484m
|
CAGR 3-Years
17%
|
CAGR 5-Years
-39%
|
CAGR 10-Years
-20%
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Income (Common)
$3.8B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-2%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Income (Common)
$4B
|
CAGR 3-Years
13%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Income (Common)
$3.9B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
10%
|
CAGR 10-Years
26%
|
See Also
What is Bone Biologics Corp's Net Income (Common)?
Net Income (Common)
-8.9m
USD
Based on the financial report for Dec 31, 2023, Bone Biologics Corp's Net Income (Common) amounts to -8.9m USD.
What is Bone Biologics Corp's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-15%
Over the last year, the Net Income (Common) growth was -505%. The average annual Net Income (Common) growth rates for Bone Biologics Corp have been -70% over the past three years , -15% over the past five years .